Vitamin D is a secosteroid hormone that possesses immunomodulatory properties and has been demonstrated to potentially influence inflammatory bowel disease (IBD) pathogenesis and activity. Epidemiologic data have associated vitamin D deficiency with an increased risk of IBD, hospitalizations, surgery, and loss of response to biologic therapy. Conversely, IBD itself can lead to vitamin D deficiency. This bidirectional relationship between vitamin D and IBD suggests the need for monitoring and repletion of vitamin D, as needed, in the IBD patient. This review discusses the role of vitamin D in IBD and provides practical guidance on vitamin D repletion.
OrholmMMunkholmPLangholzENielsenOHSorensenTIBinderV. Familial occurrence of inflammatory bowel disease. N Engl J Med. 1991;324(2):84-88.
2.
TyskCLindbergEJarnerotGFloderus-MyrhedB. Ulcerative colitis and Crohn’s disease in an unselected population of monozygotic and dizygotic twins: a study of heritability and the influence of smoking. Gut. 1988;29(7):990-996.
3.
HalfvarsonJBressoFD’AmatoMJarnerotGPetterssonSTyskC. CARD15/NOD2 polymorphisms do not explain concordance of Crohn’s disease in Swedish monozygotic twins. Dig Liver Dis. 2005;37(10):768-772.
4.
HugotJPChamaillardMZoualiHAssociation of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001;411(6837):599-603.
5.
OguraYBonenDKInoharaNA frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature. 2001;411(6837):603-606.
6.
RiouxJDXavierRJTaylorKDGenome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet. 2007;39(5):596-604.
7.
McCarrollSAHuettAKuballaPDeletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn’s disease. Nat Genet. 2008;40(9):1107-1112.
8.
GradelKONielsenHLSchonheyderHCEjlertsenTKristensenBNielsenH. Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. Gastroenterology. 2009;137(2):495-501.
9.
Garcia RodriguezLARuigomezAPanesJ. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology. 2006;130(6):1588-1594.
10.
ShawSYBlanchardJFBernsteinCN. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol. 2010;105(12):2687-2692.
11.
HouJKAbrahamBEl-SeragH. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol. 2011;106(4):563-573.
12.
NerichVMonnetEEtienneAGeographical variations of inflammatory bowel disease in France: a study based on national health insurance data. Inflamm Bowel Dis. 2006;12(3):218-226.
13.
ShivanandaSLennard-JonesJLoganRIncidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut. 1996;39(5):690-697.
14.
KhaliliHHuangESAnanthakrishnanANGeographical variation and incidence of inflammatory bowel disease among US women. Gut. 2012;61(12):1686-1692.
15.
CoppingAM. Origin of vitamin D in cod-liver oil: vitamin D content of zooplankton. Biochem J. 1934;28(4):1516-1520.
16.
HolickMF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281.
17.
HolickMFMacLaughlinJAClarkMBPhotosynthesis of previtamin D3 in human skin and the physiologic consequences. Science. 1980;210(4466):203-205.
18.
TianXQChenTCMatsuokaLYWortsmanJHolickMF. Kinetic and thermodynamic studies of the conversion of previtamin D3 to vitamin D3 in human skin. J Biol Chem. 1993;268(20):14888-14892.
19.
HolickMFMacLaughlinJADoppeltSH. Regulation of cutaneous previtamin D3 photosynthesis in man: skin pigment is not an essential regulator. Science. 1981;211(4482):590-593.
20.
WebbARDeCostaBRHolickMF. Sunlight regulates the cutaneous production of vitamin D3 by causing its photodegradation. J Clin Endocrinol Metab. 1989;68(5):882-887.
21.
BikleDDSiiteriPKRyzenEHaddadJG. Serum protein binding of 1,25-dihydroxyvitamin D: a reevaluation by direct measurement of free metabolite levels. J Clin Endocrinol Metab. 1985;61(5):969-975.
22.
BikleDDGeeEHalloranBKowalskiMARyzenEHaddadJG. Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab. 1986;63(4):954-959.
23.
PonchonGDeLucaHF. The role of the liver in the metabolism of vitamin D. J Clin Invest. 1969;48(7):1273-1279.
24.
ChengJBMotolaDLMangelsdorfDJRussellDW. De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxilase. J Biol Chem. 2003;278(39):38084-38093.
25.
FraserDRKodicekE. Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature. 1970;228(5273):764-766.
26.
HausslerMRNormanAW. Chromosomal receptor for a vitamin D metabolite. Proc Natl Acad Sci U S A. 1969;62(1):155-162.
27.
CarlbergCBendikIWyssATwo nuclear signalling pathways for vitamin D. Nature. 1993;361(6413):657-660.
28.
NishikawaJKitauraMMatsumotoMImagawaMNishiharaT. Difference and similarity of DNA sequence recognized by VDR homodimer and VDR/RXR heterodimer. Nucleic Acids Res. 1994;22(15):2902-2907.
29.
SoneTKernerSPikeJW. Vitamin D receptor interaction with specific DNA: association as a 1,25-dihydroxyvitamin D3-modulated heterodimer. J Biol Chem. 1991;266(34):23296-23305.
30.
MorrisonNAShineJFragonasJCVerkestVMcMenemyMLEismanJA. 1,25-dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene. Science. 1989;246(4934):1158-1161.
31.
MesbahMNemereIPapagerakisPExpression of a 1,25-dihydroxyvitamin D3 membrane-associated rapid-response steroid binding protein during human tooth and bone development and biomineralization. J Bone Miner Res. 2002;17(9):1588-1596.
32.
NemereIGarbiNHammerlingGHintzeKJ. Role of the 1,25D(3)-MARRS receptor in the 1,25(OH)(2)D(3)-stimulated uptake of calcium and phosphate in intestinal cells. Steroids. 2012;77(10):897-902.
33.
AbeEMiyauraCSakagamiHDifferentiation of mouse myeloid leukemia cells induced by 1 alpha, 25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A. 1981;78(8):4990-4994.
34.
ProvvediniDMTsoukasCDDeftosLJManolagasSC. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science. 1983;221(4616):1181-1183.
BaekeFKorfHOverberghLHuman T lymphocytes are direct targets of 1,25-dihydroxyvitamin D3 in the immune system. J Steroid Biochem Mol Biol. 2010;121(1-2):221-227.
37.
BhallaAKAmentoEPClemensTLHolickMFKraneSM. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab. 1983;57(6):1308-1310.
38.
ReichelHKoefflerHPNormanA. Synthesis in vitro of 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 by interferon-gamma-stimulated Wnormal human bone marrow and alveolar macrophages. J Biol Chem. 1987;262(23):10931-10937.
39.
FritscheJMondalKEhrnspergerAAndreesenRKreutzM. Regulation of 25-hydroxyvitamin D3-1 alpha-hydroxylase and production of 1 alpha,25-dihydroxyvitamin D3 by human dendritic cells. Blood. 2003;102(9):3314-3316.
40.
ChenSSimsGPChenXXGuYYLipskyPE. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol. 2007;179(3):1634-1647.
41.
StoffelsKOverberghLGiuliettiAVerlindenLBouillonRMathieuC. Immune regulation of 25-hydroxyvitamin-D3-1alpha-hydroxylase in human monocytes. J Bone Miner Res. 2006;21(1):37-47.
42.
LiuPTStengerSLiHToll-like receptor triggering of a vitamin D–mediated human antimicrobial response. Science. 2006;311(5768):1770-1773.
43.
SadeghiKWessnerBLaggnerUVitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol. 2006;36(2):361-370.
44.
KreutzMAndreesenRKrauseSWSzaboARitzEReichelH. 1,25-dihydroxyvitamin D3 production and vitamin D3 receptor expression are developmentally regulated during differentiation of human monocytes into macrophages. Blood. 1993;82(4):1300-1307.
45.
TsoukasCDProvvediniDMManolagasSC. 1,25-dihydroxyvitamin D3: a novel immunoregulatory hormone. Science. 1984;224(4656):1438-1440.
46.
ManolagasSCProvvediniDMMurrayEJTsoukasCDDeftosLJ. The antiproliferative effect of calcitriol on human peripheral blood mononuclear cells. J Clin Endocrinol Metab. 1986;63(2):394-400.
47.
PiemontiLMontiPSironiMVitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol. 2000;164(9):4443-4451.
48.
GriffinMDLutzWPhanVABachmanLAMcKeanDJKumarR. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U S A. 2001;98(12):6800-6805.
49.
PennaGAdoriniL. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol. 2000;164(5):2405-2411.
50.
AdoriniLPennaGGiarratanaNDendritic cells as key targets for immunomodulation by vitamin D receptor ligands. J Steroid Biochem Mol Biol. 2004;89-90(1-5):437-441.
51.
GregoriSGiarratanaNSmiroldoSUskokovicMAdoriniL. A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes. 2002;51(5):1367-1374.
52.
JefferyLEBurkeFMuraM1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol. 2009;183(9):5458-5467.
53.
BarratFJCuaDJBoonstraAIn vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med. 2002;195(5):603-616.
54.
GhoreishiMBachPObstJKombaMFleetJCDutzJP. Expansion of antigen-specific regulatory T cells with the topical vitamin d analog calcipotriol. J Immunol. 2009;182(10):6071-6078.
55.
DanielCSartoryNAZahnNRadekeHHSteinJM. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther. 2008;324(1):23-33.
56.
MahonBDWittkeAWeaverVCantornaMT. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem. 2003;89(5):922-932.
57.
ChangJHChaHRLeeDSSeoKYKweonMN. 1,25-Dihydroxyvitamin D3 inhibits the differentiation and migration of T(H)17 cells to protect against experimental autoimmune encephalomyelitis. PLoS One. 2010;5(9):e12925.
58.
PalmerMTLeeYKMaynardCLLineage-specific effects of 1,25-dihydroxyvitamin D(3) on the development of effector CD4 T cells. J Biol Chem. 2011;286(2):997-1004.
59.
AlroyITowersTLFreedmanLP. Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol. 1995;15(10):5789-5799.
60.
BhallaAKAmentoEPKraneSM. Differential effects of 1,25-dihydroxyvitamin D3 on human lymphocytes and monocyte/macrophages: inhibition of interleukin-2 and augmentation of interleukin-1 production. Cell Immunol. 1986;98(2):311-322.
61.
D’AmbrosioDCippitelliMCoccioloMGInhibition of IL-12 production by 1,25-dihydroxyvitamin D3: involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest. 1998;101(1):252-262.
62.
SchauberJDorschnerRACodaABInjury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest. 2007;117(3):803-811.
63.
WangTTNestelFPBourdeauVCutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004;173(5):2909-2912.
64.
GombartAFBorregaardNKoefflerHP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005;19(9):1067-1077.
65.
FroicuMZhuYCantornaMT. Vitamin D receptor is required to control gastrointestinal immunity in IL-10 knockout mice. Immunology. 2006;117(3):310-318.
MullinGELazenbyAJHarrisMLBaylessTMJamesSP. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn’s disease but not ulcerative colitis. Gastroenterology. 1992;102(5):1620-1627.
68.
MullinGEVezzaFRSampatAAbnormal IL-10 mRNA production in the intestinal mucosal lesions of inflammatory bowel disease. Gastroenterology. 1993;104:A751.
69.
FroicuMWeaverVWynnTAMcDowellMAWelshJECantornaMT. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol. 2003;17(12):2386-2392.
70.
YuSBruceDFroicuMWeaverVCantornaMT. Failure of T cell homing, reduced CD4/CD8alphaalpha intraepithelial lymphocytes, and inflammation in the gut of vitamin D receptor KO mice. Proc Natl Acad Sci U S A. 2008;105(52):20834-20839.
71.
CantornaMTMunsickCBemissCMahonBD. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr. 2000;130(11):2648-2652.
72.
ZhuYMahonBDFroicuMCantornaMT. Calcium and 1 alpha,25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol. 2005;35(1):217-224.
73.
LavernyGPennaGVetranoSEfficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. Immunol Lett. 2010;131(1):49-58.
74.
DanielCRadekeHHSartoryNAThe new low calcemic vitamin D analog 22-ene-25-oxa-vitamin D prominently ameliorates T helper cell type 1-mediated colitis in mice. J Pharmacol Exp Ther. 2006;319(2):622-631.
75.
NerichVMonnetEWeillAFine-scale geographic variations of inflammatory bowel disease in France: correlation with socioeconomic and house equipment variables. Inflamm Bowel Dis. 2010;16(5):813-821.
76.
NerichVJantchouPBoutron-RuaultMCLow exposure to sunlight is a risk factor for Crohn’s disease. Aliment Pharmacol Ther. 2011;33(8):940-945.
77.
JantchouPClavel-ChapelonFRacineAKvaskoffMCarbonnelFBoutron-RuaultMC. High residential sun exposure is associated with a low risk of incident Crohn’s disease in the prospective E3N cohort. Inflamm Bowel Dis. 2014;20(1):75-81.
78.
ArmitageELAldhousMCAndersonNIncidence of juvenile-onset Crohn’s disease in Scotland: association with northern latitude and affluence. Gastroenterology. 2004;127(4):1051-1057.
79.
AnanthakrishnanANKhaliliHHiguchiLMHigher predicted vitamin D status is associated with reduced risk of Crohn’s disease. Gastroenterology. 2012;142(3):482-489.
80.
SonnenbergAJacobsenSJWassermanIH. Periodicity of hospital admissions for inflammatory bowel disease. Am J Gastroenterol. 1994;89(6):847-851.
81.
AratariAPapiCGallettiBSeasonal variations in onset of symptoms in Crohn’s disease. Dig Liver Dis. 2006;38(5):319-323.
82.
LewisJDAberraFNLichtensteinGRBilkerWBBrensingerCStromBL. Seasonal variation in flares of inflammatory bowel disease. Gastroenterology. 2004;126(3):665-673.
83.
TyskCJarnerotG. Seasonal variation in exacerbations of ulcerative colitis. Scand J Gastroenterol. 1993;28(1):95-96.
84.
LimketkaiBNBaylessTMBrantSRHutflessSM. Lower regional and temporal ultraviolet exposure is associated with increased rates and severity of inflammatory bowel disease hospitalisation. Aliment Pharmacol Ther. 2014;40(5):508-517.
85.
AnanthakrishnanANCaganAGainerVSNormalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn’s disease. Inflamm Bowel Dis. 2013;19(9):1921-1927.
86.
UlitskyAAnanthakrishnanANNaikAVitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. JPEN J Parenter Enteral Nutr. 2011;35(3):308-316.
87.
BlanckSAberraF. Vitamin d deficiency is associated with ulcerative colitis disease activity. Dig Dis Sci. 2013;58(6):1698-1702.
88.
BenchimolEIWardLMGallagherJCEffect of calcium and vitamin D supplementation on bone mineral density in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;45(5):538-545.
89.
SiffledeenJSFedorakRNSiminoskiKRandomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn’s disease. Clin Gastroenterol Hepatol. 2005;3(2):122-132.
90.
YangLWeaverVSmithJPBingamanSHartmanTJCantornaMT. Therapeutic effect of vitamin d supplementation in a pilot study of Crohn’s patients. Clin Transl Gastroenterol. 2013;4:e33.
MihellerPMuzesGHritzIComparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn’s disease patients. Inflamm Bowel Dis. 2009;15(11):1656-1662.
93.
ZatorZACantuSMKonijetiGGPretreatment 25-hydroxyvitamin D levels and durability of anti-tumor necrosis factor-alpha therapy in inflammatory bowel diseases. JPEN J Parenter Enteral Nutr. 2014;38(3):385-391.
94.
Santos-AntunesJNunesACLopesSMacedoG. The relevance of vitamin D and antinuclear antibodies in patients with inflammatory bowel disease under anti-TNF treatment: a prospective study. Inflamm Bowel Dis. 2016;22(5):1101-1106.
95.
RosenCJ. Clinical practice: vitamin D insufficiency. N Engl J Med. 2011;364(3):248-254.
96.
AutierPBoniolMPizotCMullieP. Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol. 2014;2(1):76-89.
97.
FarrayeFANimitphongHStucchiAUse of a novel vitamin D bioavailability test demonstrates that vitamin D absorption is decreased in patients with quiescent Crohn’s disease. Inflamm Bowel Dis. 2011;17(10):2116-2121.
98.
TajikaMMatsuuraANakamuraTRisk factors for vitamin D deficiency in patients with Crohn’s disease. J Gastroenterol. 2004;39(6):527-533.
99.
LeichtmannGABengoaJMBoltMJSitrinMD. Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohn’s disease and intestinal resection. Am J Clin Nutr. 1991;54(3):548-552.
100.
BuckleyLMLeibESCartularoKSVacekPMCooperSM. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996;125(12):961-968.
101.
LukertBPRaiszLG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990;112(5):352-364.
102.
De SevauxRGHoitsmaAJCorstensFHWetzelsJF. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol. 2002;13(6):1608-1614.
103.
CompstonJEHortonLW. Oral 25-hydroxyvitain D3 in treatment of osteomalacia associated with ileal resection and cholestyramine therapy. Gastroenterology. 1978;74(5, pt 1):900-902.
104.
KrejsGJNicarMJZerwekhJENormanDAKaneMGPakCY. Effect of 1,25-dihydroxyvitamin D3 on calcium and magnesium absorption in the healthy human jejunum and ileum. Am J Med. 1983;75(6):973-976.
105.
HlavatyTKrajcovicovaAKollerTHigher vitamin D serum concentration increases health related quality of life in patients with inflammatory bowel diseases. World J Gastroenterol. 2014;20(42):15787-15796.
106.
ArmasLAHollisBWHeaneyRP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 2004;89(11):5387-5391.
107.
HeaneyRPReckerRRGroteJHorstRLArmasLA. Vitamin D(3) is more potent than vitamin D(2) in humans. J Clin Endocrinol Metab. 2011;96(3):E447-E452.
108.
PappaHMMitchellPDJiangHTreatment of vitamin D insufficiency in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing three regimens. J Clin Endocrinol Metab. 2012;97(6):2134-2142.
109.
VogelsangHSchoflRTillingerWFerenciPGanglA. 25-Hydroxyvitamin D absorption in patients with Crohn’s disease and with pancreatic insufficiency. Wien Klin Wochenschr. 1997;109(17):678-682.
110.
RossAC. The 2011 report on dietary reference intakes for calcium and vitamin D. Public Health Nutr. 2011;14(5):938-939.
111.
HolickMFBinkleyNCBischoff-FerrariHAEvaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911-1930.
112.
GargMLubelJSSparrowMPHoltSGGibsonPR. Review article: vitamin D and inflammatory bowel disease—established concepts and future directions. Aliment Pharmacol Ther. 2012;36(4):324-344.
113.
HolickMF. Sunlight “D”ilemma: risk of skin cancer or bone disease and muscle weakness. Lancet. 2001;357(9249):4-6.
114.
Bischoff-FerrariHAShaoADawson-HughesBHathcockJGiovannucciEWillettWC. Benefit-risk assessment of vitamin D supplementation. Osteoporos Int. 2010;21(7):1121-1132.
115.
LeventisPKielyPD. The tolerability and biochemical effects of high-dose bolus vitamin D2 and D3 supplementation in patients with vitamin D insufficiency. Scand J Rheumatol. 2009;38(2):149-153.
116.
BaconCJGambleGDHorneAMScottMAReidIR. High-dose oral vitamin D3 supplementation in the elderly. Osteoporos Int. 2009;20(8):1407-1415.
117.
HathcockJNShaoAViethRHeaneyR. Risk assessment for vitamin D. Am J Clin Nutr. 2007;85(1):6-18.
118.
ViethR. Vitamin D toxicity, policy, and science. J Bone Miner Res. 2007;22(suppl 2):V64-V68.
119.
JonesG. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008;88(2):582S-586S.
120.
BraamLAHoeksAPBrounsFHamulyakKGerichhausenMJVermeerC. Beneficial effects of vitamins D and K on the elastic properties of the vessel wall in postmenopausal women: a follow-up study. Thromb Haemost. 2004;91(2):373-380.
121.
YangBCampbellPTGapsturSMCalcium intake and mortality from all causes, cancer, and cardiovascular disease: the Cancer Prevention Study II Nutrition Cohort. Am J Clin Nutr. 2016;103(3):886-894.
122.
PappaHMMitchellPDJiangHMaintenance of optimal vitamin D status in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing two regimens. J Clin Endocrinol Metab. 2014;99(9):3408-3417.
123.
RafteryTMartineauARGreillerCLEffects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn’s disease: results from a randomised double-blind placebo-controlled study. United European Gastroenterol J. 2015;3(3):294-302.
